234 related articles for article (PubMed ID: 24168112)
1. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
Uehara T; Kanazawa T; Mizukami H; Uchibori R; Tsukahara T; Urabe M; Kume A; Misawa K; Carey TE; Suzuki M; Ichimura K; Ozawa K
Cancer Sci; 2014 Jan; 105(1):72-80. PubMed ID: 24168112
[TBL] [Abstract][Full Text] [Related]
2. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Kanazawa T; Kommareddi PK; Iwashita T; Kumar B; Misawa K; Misawa Y; Jang I; Nair TS; Iino Y; Carey TE
Clin Cancer Res; 2009 Apr; 15(7):2222-30. PubMed ID: 19276245
[TBL] [Abstract][Full Text] [Related]
3. Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC.
Kanazawa T; Misawa K; Misawa Y; Maruta M; Uehara T; Kawada K; Nagatomo T; Ichimura K
Mol Med Rep; 2014 Sep; 10(3):1289-94. PubMed ID: 25017118
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
5. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma.
Kanazawa T; Misawa K; Carey TE
Expert Opin Ther Targets; 2010 Mar; 14(3):289-302. PubMed ID: 20148716
[TBL] [Abstract][Full Text] [Related]
6. Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma.
Banerjee R; Henson BS; Russo N; Tsodikov A; D'Silva NJ
Cell Signal; 2011 Jul; 23(7):1110-8. PubMed ID: 21345369
[TBL] [Abstract][Full Text] [Related]
7. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
9. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
10. Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2).
Tofighi R; Joseph B; Xia S; Xu ZQ; Hamberger B; Hökfelt T; Ceccatelli S
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2717-22. PubMed ID: 18272487
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
13. Galanin mediates tumor-induced immunosuppression in head and neck squamous cell carcinoma.
de Medeiros MC; Liu M; Banerjee R; Bellile E; D'Silva NJ; Rossa C
Cell Oncol (Dordr); 2022 Apr; 45(2):241-256. PubMed ID: 35267186
[TBL] [Abstract][Full Text] [Related]
14. Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells.
Berger A; Lang R; Moritz K; Santic R; Hermann A; Sperl W; Kofler B
Endocrinology; 2004 Feb; 145(2):500-7. PubMed ID: 14592962
[TBL] [Abstract][Full Text] [Related]
15. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
17. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.
Lee J; Jiffar T; Kupferman ME
PLoS One; 2012; 7(1):e30246. PubMed ID: 22276165
[TBL] [Abstract][Full Text] [Related]
18. Direct inhibition of interleukin-2 receptor alpha-mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer cells.
Kuhn DJ; Dou QP
J Cell Biochem; 2005 May; 95(2):379-90. PubMed ID: 15779002
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
[TBL] [Abstract][Full Text] [Related]
20. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Kanazawa T; Iwashita T; Kommareddi P; Nair T; Misawa K; Misawa Y; Ueda Y; Tono T; Carey TE
Oncogene; 2007 Aug; 26(39):5762-71. PubMed ID: 17384686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
